{"parse":{"title":"Neglected tropical disease research and development","pageid":30916247,"revid":844372195,"text":{"*":"<div class=\"mw-parser-output\"><table class=\"plainlinks metadata ambox ambox-style ambox-Cleanup\" role=\"presentation\"><tbody><tr><td class=\"mbox-image\"><div style=\"width:52px\"><img alt=\"\" src=\"//upload.wikimedia.org/wikipedia/en/thumb/f/f2/Edit-clear.svg/40px-Edit-clear.svg.png\" width=\"40\" height=\"40\" srcset=\"//upload.wikimedia.org/wikipedia/en/thumb/f/f2/Edit-clear.svg/60px-Edit-clear.svg.png 1.5x, //upload.wikimedia.org/wikipedia/en/thumb/f/f2/Edit-clear.svg/80px-Edit-clear.svg.png 2x\" data-file-width=\"48\" data-file-height=\"48\" /></div></td><td class=\"mbox-text\"><div class=\"mbox-text-span\">This article may <b>require <a href=\"/wiki/Wikipedia:Cleanup\" title=\"Wikipedia:Cleanup\">cleanup</a></b> to meet Wikipedia's <a href=\"/wiki/Wikipedia:Manual_of_Style\" title=\"Wikipedia:Manual of Style\">quality standards</a>.<span class=\"hide-when-compact\"> No <a href=\"/wiki/Template:Cleanup/doc\" title=\"Template:Cleanup/doc\">cleanup reason</a> has been specified. Please help <a class=\"external text\" href=\"//en.wikipedia.org/w/index.php?title=Neglected_tropical_disease_research_and_development&amp;action=edit\">improve this article</a> if you can.</span>  <small><i>(July 2011)</i></small><small class=\"hide-when-compact\"><i> (<a href=\"/wiki/Help:Maintenance_template_removal\" title=\"Help:Maintenance template removal\">Learn how and when to remove this template message</a>)</i></small></div></td></tr></tbody></table>\n<p><b>Neglected tropical diseases</b> (NTDs) are a set of infectious diseases affecting an estimated 1.4 billion people worldwide.  The classification of this group of <a href=\"/wiki/Neglected_tropical_diseases\" title=\"Neglected tropical diseases\">neglected diseases</a> is linked to their frequent neglect in public and private sector expenditure and attention at local, national, and international levels, and their concentration among the poor.  <a href=\"/wiki/Research_and_development\" title=\"Research and development\">Research and development</a> yielding safe, effective drugs and vaccines for their treatment and prevention has been recognized as a global health priority.\n</p>\n<div id=\"toc\" class=\"toc\"><input type=\"checkbox\" role=\"button\" id=\"toctogglecheckbox\" class=\"toctogglecheckbox\" style=\"display:none\" /><div class=\"toctitle\" lang=\"en\" dir=\"ltr\"><h2>Contents</h2><span class=\"toctogglespan\"><label class=\"toctogglelabel\" for=\"toctogglecheckbox\"></label></span></div>\n<ul>\n<li class=\"toclevel-1 tocsection-1\"><a href=\"#Overview\"><span class=\"tocnumber\">1</span> <span class=\"toctext\">Overview</span></a></li>\n<li class=\"toclevel-1 tocsection-2\"><a href=\"#NTD_list\"><span class=\"tocnumber\">2</span> <span class=\"toctext\">NTD list</span></a></li>\n<li class=\"toclevel-1 tocsection-3\"><a href=\"#Deficient_market\"><span class=\"tocnumber\">3</span> <span class=\"toctext\">Deficient market</span></a></li>\n<li class=\"toclevel-1 tocsection-4\"><a href=\"#Policy_initiatives\"><span class=\"tocnumber\">4</span> <span class=\"toctext\">Policy initiatives</span></a>\n<ul>\n<li class=\"toclevel-2 tocsection-5\"><a href=\"#Public_private_partnerships\"><span class=\"tocnumber\">4.1</span> <span class=\"toctext\">Public private partnerships</span></a></li>\n<li class=\"toclevel-2 tocsection-6\"><a href=\"#R&amp;D_capacity_building_in_middle_income_countries\"><span class=\"tocnumber\">4.2</span> <span class=\"toctext\">R&amp;D capacity building in middle income countries</span></a></li>\n<li class=\"toclevel-2 tocsection-7\"><a href=\"#Innovation_prizes_and_grants\"><span class=\"tocnumber\">4.3</span> <span class=\"toctext\">Innovation prizes and grants</span></a></li>\n<li class=\"toclevel-2 tocsection-8\"><a href=\"#FDA_priority_review_vouchers_(PRV)\"><span class=\"tocnumber\">4.4</span> <span class=\"toctext\">FDA priority review vouchers (PRV)</span></a></li>\n<li class=\"toclevel-2 tocsection-9\"><a href=\"#Open_source_collaboration_initiatives\"><span class=\"tocnumber\">4.5</span> <span class=\"toctext\">Open source collaboration initiatives</span></a></li>\n</ul>\n</li>\n<li class=\"toclevel-1 tocsection-10\"><a href=\"#References\"><span class=\"tocnumber\">5</span> <span class=\"toctext\">References</span></a></li>\n<li class=\"toclevel-1 tocsection-11\"><a href=\"#Further_reading\"><span class=\"tocnumber\">6</span> <span class=\"toctext\">Further reading</span></a></li>\n<li class=\"toclevel-1 tocsection-12\"><a href=\"#External_links\"><span class=\"tocnumber\">7</span> <span class=\"toctext\">External links</span></a></li>\n</ul>\n</div>\n\n<h2><span class=\"mw-headline\" id=\"Overview\">Overview</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=Neglected_tropical_disease_research_and_development&amp;action=edit&amp;section=1\" title=\"Edit section: Overview\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h2>\n<div class=\"thumb tright\"><div class=\"thumbinner\" style=\"width:222px;\"><a href=\"/wiki/File:Ivermectin_skeletal.svg\" class=\"image\"><img alt=\"\" src=\"//upload.wikimedia.org/wikipedia/commons/thumb/3/3d/Ivermectin_skeletal.svg/220px-Ivermectin_skeletal.svg.png\" width=\"220\" height=\"241\" class=\"thumbimage\" srcset=\"//upload.wikimedia.org/wikipedia/commons/thumb/3/3d/Ivermectin_skeletal.svg/330px-Ivermectin_skeletal.svg.png 1.5x, //upload.wikimedia.org/wikipedia/commons/thumb/3/3d/Ivermectin_skeletal.svg/440px-Ivermectin_skeletal.svg.png 2x\" data-file-width=\"1360\" data-file-height=\"1490\" /></a>  <div class=\"thumbcaption\"><div class=\"magnify\"><a href=\"/wiki/File:Ivermectin_skeletal.svg\" class=\"internal\" title=\"Enlarge\"></a></div>The structure of two of the ivermectins, an important class of drug in the control of Onchocerciasis.</div></div></div>\n<p>Neglected tropical diseases are a set of <a href=\"/wiki/Infectious_disease\" class=\"mw-redirect\" title=\"Infectious disease\">infectious communicable diseases</a> arising from a diverse group of parasitic worms, bacteria, and vector-borne protozoa.<sup id=\"cite_ref-I_1-0\" class=\"reference\"><a href=\"#cite_note-I-1\">&#91;1&#93;</a></sup>  The NTDs result in an estimated 534,000 deaths annually<sup id=\"cite_ref-K2_2-0\" class=\"reference\"><a href=\"#cite_note-K2-2\">&#91;2&#93;</a></sup> and 57 million <a href=\"/wiki/Disability-adjusted_life_years\" class=\"mw-redirect\" title=\"Disability-adjusted life years\">disability-adjusted life years</a> (DALYs) lost.<sup id=\"cite_ref-K_3-0\" class=\"reference\"><a href=\"#cite_note-K-3\">&#91;3&#93;</a></sup> The social, economic, and health burden of these diseases falls primarily on <a href=\"/wiki/Developing_country\" title=\"Developing country\">low and middle income countries</a> where the diseases are most prevalent.<sup id=\"cite_ref-G_4-0\" class=\"reference\"><a href=\"#cite_note-G-4\">&#91;4&#93;</a></sup>  The NTDs represent the sixth greatest global health burden in terms of DALYs, equal to or potentially surpassing global malaria burden.<sup id=\"cite_ref-K_3-1\" class=\"reference\"><a href=\"#cite_note-K-3\">&#91;3&#93;</a></sup><sup id=\"cite_ref-L_5-0\" class=\"reference\"><a href=\"#cite_note-L-5\">&#91;5&#93;</a></sup>\n</p><p>NTD interventions include both programs to address environmental and <a href=\"/wiki/Social_determinants_of_health\" title=\"Social determinants of health\">social determinants of health</a> (e.g., vector control, water quality, sanitation), and programs offering <a href=\"/wiki/Mass_drug_administration\" title=\"Mass drug administration\">mass drug administration</a> for disease prevention and treatment.  Drug treatments exist<sup id=\"cite_ref-T_6-0\" class=\"reference\"><a href=\"#cite_note-T-6\">&#91;6&#93;</a></sup> to confront many of the NTDs and represent some of the world's <a href=\"/wiki/Essential_medicines\" title=\"Essential medicines\">essential medicines</a>.<sup id=\"cite_ref-Y_7-0\" class=\"reference\"><a href=\"#cite_note-Y-7\">&#91;7&#93;</a></sup><sup id=\"cite_ref-E_8-0\" class=\"reference\"><a href=\"#cite_note-E-8\">&#91;8&#93;</a></sup>  Despite significant health and economic improvements using available medicines,<sup id=\"cite_ref-G_4-1\" class=\"reference\"><a href=\"#cite_note-G-4\">&#91;4&#93;</a></sup><sup id=\"cite_ref-D3_9-0\" class=\"reference\"><a href=\"#cite_note-D3-9\">&#91;9&#93;</a></sup><sup id=\"cite_ref-D4_10-0\" class=\"reference\"><a href=\"#cite_note-D4-10\">&#91;10&#93;</a></sup><sup id=\"cite_ref-Z2_11-0\" class=\"reference\"><a href=\"#cite_note-Z2-11\">&#91;11&#93;</a></sup> the low number of new compounds being researched and developed for NTDs is an ongoing and significant challenge.<sup id=\"cite_ref-Y_7-1\" class=\"reference\"><a href=\"#cite_note-Y-7\">&#91;7&#93;</a></sup><sup id=\"cite_ref-Z_12-0\" class=\"reference\"><a href=\"#cite_note-Z-12\">&#91;12&#93;</a></sup><sup id=\"cite_ref-D2_13-0\" class=\"reference\"><a href=\"#cite_note-D2-13\">&#91;13&#93;</a></sup>  The dearth of candidates in pharmaceutical company <a href=\"/wiki/Drug_pipeline\" title=\"Drug pipeline\">drug pipelines</a> is primarily attributed to the high costs of drug development and the fact that NTDs are concentrated among the worlds' poor.<sup id=\"cite_ref-Z_12-1\" class=\"reference\"><a href=\"#cite_note-Z-12\">&#91;12&#93;</a></sup><sup id=\"cite_ref-A_14-0\" class=\"reference\"><a href=\"#cite_note-A-14\">&#91;14&#93;</a></sup> Other disincentives to investment include weak existing infrastructure for distribution and sales, and concerns regarding intellectual property protection.<sup id=\"cite_ref-Z2_11-1\" class=\"reference\"><a href=\"#cite_note-Z2-11\">&#91;11&#93;</a></sup>  However, the major stakeholders in NTD drug development\u2014governments, foundations, pharmaceutical companies, academia, and <a href=\"/wiki/Non-governmental_organization\" title=\"Non-governmental organization\">NGOs</a>\u2014are involved in activities to help address the research and development shortfall and meet the many challenges presented by neglected tropical diseases.<sup id=\"cite_ref-Q_15-0\" class=\"reference\"><a href=\"#cite_note-Q-15\">&#91;15&#93;</a></sup> Initiatives include public private partnerships, global R&amp;D capacity building, priority vouchers to speed drug approval processes, open source scientific collaborations, and harmonization of global governance structures concerning NTDs.\n</p>\n<h2><span class=\"mw-headline\" id=\"NTD_list\">NTD list</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=Neglected_tropical_disease_research_and_development&amp;action=edit&amp;section=2\" title=\"Edit section: NTD list\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h2>\n<p>The diseases considered neglected tropical diseases vary. <a href=\"/wiki/Malaria\" title=\"Malaria\">Malaria</a>, <a href=\"/wiki/HIV/AIDS\" title=\"HIV/AIDS\">HIV</a>, and <a href=\"/wiki/Tuberculosis\" title=\"Tuberculosis\">tuberculosis</a> have received an amount of public attention and increased funding to no longer be considered neglected by some researchers.  Outside \"The Big Three\", the seven most prevalent neglected tropical diseases in order of their global prevalence are <a href=\"/wiki/Ascariasis\" title=\"Ascariasis\">ascariasis</a>, <a href=\"/wiki/Trichuriasis\" title=\"Trichuriasis\">trichuriasis</a>, <a href=\"/wiki/Hookworm_infections\" class=\"mw-redirect\" title=\"Hookworm infections\">hookworm infection</a>, <a href=\"/wiki/Schistosomiasis\" title=\"Schistosomiasis\">schistosomiasis</a>, <a href=\"/wiki/Lymphatic_filariasis\" title=\"Lymphatic filariasis\">lymphatic filariasis</a>, and <a href=\"/wiki/Trachoma\" title=\"Trachoma\">trachoma</a>.<sup id=\"cite_ref-K_3-2\" class=\"reference\"><a href=\"#cite_note-K-3\">&#91;3&#93;</a></sup>  These seven are among a larger list of thirteen major NTDs: <a href=\"/wiki/Onchocerciasis\" title=\"Onchocerciasis\">onchocerciasis</a>, <a href=\"/wiki/Leishmaniasis\" title=\"Leishmaniasis\">leishmaniasis</a>, <a href=\"/wiki/Chagas%27_disease\" class=\"mw-redirect\" title=\"Chagas&#39; disease\">Chagas' disease</a>, <a href=\"/wiki/Leprosy\" title=\"Leprosy\">leprosy</a>, <a href=\"/wiki/Human_African_trypanosomiasis\" class=\"mw-redirect\" title=\"Human African trypanosomiasis\">Human African trypanosomiasis</a> (sleeping sickness), <a href=\"/wiki/Dracunculiasis\" title=\"Dracunculiasis\">Dracunculiasis</a>, and <a href=\"/wiki/Buruli_ulcer\" title=\"Buruli ulcer\">Buruli ulcer</a>.<sup id=\"cite_ref-K_3-3\" class=\"reference\"><a href=\"#cite_note-K-3\">&#91;3&#93;</a></sup>\n</p><p>The <a href=\"/wiki/World_Health_Organization\" title=\"World Health Organization\">World Health Organization</a>'s 2010 report dedicated to neglected tropical diseases offers an expanded list including <a href=\"/wiki/Dengue_fever\" title=\"Dengue fever\">dengue</a>, <a href=\"/wiki/Rabies\" title=\"Rabies\">rabies</a>, <a href=\"/wiki/Yaws\" title=\"Yaws\">yaws</a>, <a href=\"/wiki/Cysticercosis\" title=\"Cysticercosis\">cysticercosis</a>, <a href=\"/wiki/Echinococcosis\" title=\"Echinococcosis\">echinococcosis</a>, and <a href=\"/wiki/Trematode_infection\" class=\"mw-redirect\" title=\"Trematode infection\">foodborne trematode infections</a>.<sup id=\"cite_ref-Z3_16-0\" class=\"reference\"><a href=\"#cite_note-Z3-16\">&#91;16&#93;</a></sup>\n</p>\n<table class=\"wikitable sortable collapsible\">\n<caption>Neglected Tropical Diseases Worldwide Burden\n</caption>\n<tbody><tr>\n<th>Disease</th>\n<th>DALYs (million)</th>\n<th>Deaths/Yr</th>\n<th>Global Prevalence (million)</th>\n<th>Population at Risk (million)\n</th></tr>\n<tr>\n<td><a href=\"/wiki/Schistosomiasis\" title=\"Schistosomiasis\">Schistosomiasis</a></td>\n<td>4.5</td>\n<td>280,000</td>\n<td>207</td>\n<td>780\n</td></tr>\n<tr>\n<td><a href=\"/wiki/Hookworm\" title=\"Hookworm\">Hookworm</a></td>\n<td>22.1</td>\n<td>65,000</td>\n<td>576</td>\n<td>3200\n</td></tr>\n<tr>\n<td><a href=\"/wiki/Ascariasis\" title=\"Ascariasis\">Ascariasis</a></td>\n<td>10.5</td>\n<td>60,000</td>\n<td>807</td>\n<td>4200\n</td></tr>\n<tr>\n<td><a href=\"/wiki/Leishmaniasis\" title=\"Leishmaniasis\">Leishmaniasis</a></td>\n<td>2.1</td>\n<td>51,000</td>\n<td>12</td>\n<td>350\n</td></tr>\n<tr>\n<td><a href=\"/wiki/Trypanosomiasis\" title=\"Trypanosomiasis\">Trypanosomiasis</a></td>\n<td>1.5</td>\n<td>48,000</td>\n<td>0.3</td>\n<td>60\n</td></tr>\n<tr>\n<td><a href=\"/wiki/Chagas_disease\" title=\"Chagas disease\">Chagas disease</a></td>\n<td>0.7</td>\n<td>14,000</td>\n<td>8</td>\n<td>25\n</td></tr>\n<tr>\n<td><a href=\"/wiki/Trichuriasis\" title=\"Trichuriasis\">Trichuriasis</a></td>\n<td>6.4</td>\n<td>10,000</td>\n<td>604</td>\n<td>3200\n</td></tr>\n<tr>\n<td><a href=\"/wiki/Leprosy\" title=\"Leprosy\">Leprosy</a></td>\n<td>0.2</td>\n<td>6,000</td>\n<td>0.4</td>\n<td>ND\n</td></tr>\n<tr>\n<td><a href=\"/wiki/Lymphatic_filariasis\" title=\"Lymphatic filariasis\">Lymphatic filariasis</a></td>\n<td>5.8</td>\n<td>0</td>\n<td>120</td>\n<td>1300\n</td></tr>\n<tr>\n<td><a href=\"/wiki/Trachoma\" title=\"Trachoma\">Trachoma</a></td>\n<td>2.3</td>\n<td>0</td>\n<td>84</td>\n<td>590\n</td></tr>\n<tr>\n<td><a href=\"/wiki/Onchocerciasis\" title=\"Onchocerciasis\">Onchocerciasis</a></td>\n<td>0.5</td>\n<td>0</td>\n<td>37</td>\n<td>90\n</td></tr>\n<tr>\n<td><a href=\"/wiki/Cryptococcosis\" title=\"Cryptococcosis\">Cryptococcosis</a></td>\n<td>12</td>\n<td>400,000</td>\n<td>1</td>\n<td>8\n</td></tr></tbody></table>\n<p>ND=Not Determined<sup id=\"cite_ref-K2_2-1\" class=\"reference\"><a href=\"#cite_note-K2-2\">&#91;2&#93;</a></sup><sup id=\"cite_ref-K_3-4\" class=\"reference\"><a href=\"#cite_note-K-3\">&#91;3&#93;</a></sup>\n</p>\n<h2><span class=\"mw-headline\" id=\"Deficient_market\">Deficient market</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=Neglected_tropical_disease_research_and_development&amp;action=edit&amp;section=3\" title=\"Edit section: Deficient market\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h2>\n<p>In their 2002 review of the U.S. <a href=\"/wiki/Food_and_Drug_Administration_(United_States)\" class=\"mw-redirect\" title=\"Food and Drug Administration (United States)\">Food and Drug Administration</a> (FDA) databases and the <a href=\"/wiki/European_Medicines_Agency\" title=\"European Medicines Agency\">European Agency for the Evaluation of Medicinal Products</a>, Troullier <i>et al</i> found that 16 out of 1393 new chemical entities were approved for NTDs between 1975 and 1999 (~1%).<sup id=\"cite_ref-Y_7-2\" class=\"reference\"><a href=\"#cite_note-Y-7\">&#91;7&#93;</a></sup>  Cohen <i>et al</i> revisited the data and using the same methodology found 32 new chemical entities during the time period.<sup id=\"cite_ref-E_8-1\" class=\"reference\"><a href=\"#cite_note-E-8\">&#91;8&#93;</a></sup> In a second analysis using an expanded list of NTDs based on the G-FINDER survey,<sup id=\"cite_ref-Z4_17-0\" class=\"reference\"><a href=\"#cite_note-Z4-17\">&#91;17&#93;</a></sup> the number was slightly higher, with 46 new drugs and vaccines approved (~3% of the total including HIV drugs).<sup id=\"cite_ref-E_8-2\" class=\"reference\"><a href=\"#cite_note-E-8\">&#91;8&#93;</a></sup>  Between 2000 and 2009, there has been some increase with an additional 26 newly approved drugs and vaccines for NTDs.<sup id=\"cite_ref-E_8-3\" class=\"reference\"><a href=\"#cite_note-E-8\">&#91;8&#93;</a></sup>\n</p><p>A number of factors are recognized as contributing to the low number. The barrier most reported is the high cost of drug development. Estimates are that pharmaceutical companies' development costs to approval fall between $500 million and $2 billion.<sup id=\"cite_ref-A2_18-0\" class=\"reference\"><a href=\"#cite_note-A2-18\">&#91;18&#93;</a></sup> DiMasi, Hansen, and Grabowski calculated an average of $802 million in year 2000 dollars.<sup id=\"cite_ref-A1_19-0\" class=\"reference\"><a href=\"#cite_note-A1-19\">&#91;19&#93;</a></sup> Furthermore, the time that drugs are approved for use averages seven years out of the twenty years on-patent, meaning a tendency for the market to focus on diseases of developed nations where high prices can be used to recoup research and development costs, and subsidize failed R&amp;D efforts.  In short, NTD research and development is considered a high investment risk given that NTDs predominantly affect the poor in low and middle income countries.<sup id=\"cite_ref-Z_12-2\" class=\"reference\"><a href=\"#cite_note-Z-12\">&#91;12&#93;</a></sup><sup id=\"cite_ref-A_14-1\" class=\"reference\"><a href=\"#cite_note-A-14\">&#91;14&#93;</a></sup>  Additional barriers include drug safety regulatory requirements, intellectual property protection problems, and poor infrastructure for distribution and sales.<sup id=\"cite_ref-Z2_11-2\" class=\"reference\"><a href=\"#cite_note-Z2-11\">&#91;11&#93;</a></sup><sup id=\"cite_ref-Z_12-3\" class=\"reference\"><a href=\"#cite_note-Z-12\">&#91;12&#93;</a></sup>\n</p><p>Although drug companies have not invested heavily in the NTDs, in several cases, rather than focus on profits, some have decided to donate key drugs to address NTDs. For example, Merk has had a program since the mid-1980s to donate ivermectin (Mectizan) indefinitely to support the global fight of onchoceriasis.  GlaxoSmithKline and several other large pharmaceutical companies have donation programs as well.  Drug donation however, does not ameliorate the deficiency of new chemical entities being researched and developed.  This is especially of concern with reports of emerging resistance among existing drugs.<sup id=\"cite_ref-X_20-0\" class=\"reference\"><a href=\"#cite_note-X-20\">&#91;20&#93;</a></sup><sup id=\"cite_ref-V_21-0\" class=\"reference\"><a href=\"#cite_note-V-21\">&#91;21&#93;</a></sup>\n</p>\n<h2><span class=\"mw-headline\" id=\"Policy_initiatives\">Policy initiatives</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=Neglected_tropical_disease_research_and_development&amp;action=edit&amp;section=4\" title=\"Edit section: Policy initiatives\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h2>\n<h3><span class=\"mw-headline\" id=\"Public_private_partnerships\">Public private partnerships</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=Neglected_tropical_disease_research_and_development&amp;action=edit&amp;section=5\" title=\"Edit section: Public private partnerships\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h3>\n<div class=\"thumb tright\"><div class=\"thumbinner\" style=\"width:222px;\"><a href=\"/wiki/File:Remy_Steinegger_-_World_Economic_Forum_-_Melinda_French_Gates,_Bill_Gates_-_World_Economic_Forum_Annual_Meeting_Davos_2009_(by-sa).jpg\" class=\"image\"><img alt=\"\" src=\"//upload.wikimedia.org/wikipedia/commons/thumb/1/1b/Remy_Steinegger_-_World_Economic_Forum_-_Melinda_French_Gates%2C_Bill_Gates_-_World_Economic_Forum_Annual_Meeting_Davos_2009_%28by-sa%29.jpg/220px-Remy_Steinegger_-_World_Economic_Forum_-_Melinda_French_Gates%2C_Bill_Gates_-_World_Economic_Forum_Annual_Meeting_Davos_2009_%28by-sa%29.jpg\" width=\"220\" height=\"122\" class=\"thumbimage\" srcset=\"//upload.wikimedia.org/wikipedia/commons/thumb/1/1b/Remy_Steinegger_-_World_Economic_Forum_-_Melinda_French_Gates%2C_Bill_Gates_-_World_Economic_Forum_Annual_Meeting_Davos_2009_%28by-sa%29.jpg/330px-Remy_Steinegger_-_World_Economic_Forum_-_Melinda_French_Gates%2C_Bill_Gates_-_World_Economic_Forum_Annual_Meeting_Davos_2009_%28by-sa%29.jpg 1.5x, //upload.wikimedia.org/wikipedia/commons/thumb/1/1b/Remy_Steinegger_-_World_Economic_Forum_-_Melinda_French_Gates%2C_Bill_Gates_-_World_Economic_Forum_Annual_Meeting_Davos_2009_%28by-sa%29.jpg/440px-Remy_Steinegger_-_World_Economic_Forum_-_Melinda_French_Gates%2C_Bill_Gates_-_World_Economic_Forum_Annual_Meeting_Davos_2009_%28by-sa%29.jpg 2x\" data-file-width=\"4096\" data-file-height=\"2276\" /></a>  <div class=\"thumbcaption\"><div class=\"magnify\"><a href=\"/wiki/File:Remy_Steinegger_-_World_Economic_Forum_-_Melinda_French_Gates,_Bill_Gates_-_World_Economic_Forum_Annual_Meeting_Davos_2009_(by-sa).jpg\" class=\"internal\" title=\"Enlarge\"></a></div>Melinda and Bill Gates speak during press conference at the World Economic Forum in Davos, Switzerland, January 30, 2009.</div></div></div>\n<p>Governments, foundations, the non-profit sector, and private sector have found new connections to help address market deficiencies by providing funding support and spreading both the costs and risks of NTD research and development.  The proliferation of <a href=\"/wiki/Public_Private_Partnerships\" class=\"mw-redirect\" title=\"Public Private Partnerships\">public private partnerships</a> (PPPs) has been recognized as a key innovation in the past decade, helping to unlock existing and new resources.\n</p><p>Major PPPs for NTDs include: the <a href=\"/wiki/Sabin_Vaccine_Institute\" title=\"Sabin Vaccine Institute\">Sabin Vaccine Institute</a>, Norvartis Vaccines Institute for Global Health, MSD Wellcome Trust <a href=\"/wiki/Hilleman_Laboratories\" title=\"Hilleman Laboratories\">Hilleman Laboratories</a>, Infectious Diseases Research Institute, <a href=\"/wiki/Institut_Pasteur\" class=\"mw-redirect\" title=\"Institut Pasteur\">Institut Pasteur</a> and <a href=\"/wiki/INSERM\" class=\"mw-redirect\" title=\"INSERM\">INSERM</a>, WIPO Re:Search, and the <a href=\"/wiki/International_Vaccine_Institute\" title=\"International Vaccine Institute\">International Vaccine Institute</a>.<sup id=\"cite_ref-A_14-2\" class=\"reference\"><a href=\"#cite_note-A-14\">&#91;14&#93;</a></sup>  Likewise, a number of new academic drug development centers have been created in recent years drawing in industry partners.  Support for these centers is frequently traced to the <a href=\"/wiki/Bill_and_Melinda_Gates_Foundation\" class=\"mw-redirect\" title=\"Bill and Melinda Gates Foundation\">Bill and Melinda Gates Foundation</a>, the <a href=\"/wiki/Sandler_Foundation\" title=\"Sandler Foundation\">Sandler Foundation</a>, and the <a href=\"/wiki/Wellcome_Trust\" title=\"Wellcome Trust\">Wellcome Trust</a>.<sup id=\"cite_ref-U_22-0\" class=\"reference\"><a href=\"#cite_note-U-22\">&#91;22&#93;</a></sup>\n</p>\n<h3><span id=\"R.26D_capacity_building_in_middle_income_countries\"></span><span class=\"mw-headline\" id=\"R&amp;D_capacity_building_in_middle_income_countries\">R&amp;D capacity building in middle income countries</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=Neglected_tropical_disease_research_and_development&amp;action=edit&amp;section=6\" title=\"Edit section: R&amp;D capacity building in middle income countries\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h3>\n<p>Growing NTD research and development capacity in middle income countries is an area of policy interest.  A 2009 study of biotechnology companies in India, China, Brazil, and South Africa revealed sixty-two NTD products in development and on the market out of approximately five hundred products offered (~14%).  When products to fight HIV, malaria, and TB were included in the analysis, the number increased to one hundred twenty-three products, approximately 25% of the total products offered.\n</p><p>Researchers have argued that unlike most multinationals, small and mid-sized \"Global South\" companies see significant business opportunities in the development of NTD-related diagnostics, biologics, pharmaceuticals, and services.<sup id=\"cite_ref-J_23-0\" class=\"reference\"><a href=\"#cite_note-J-23\">&#91;23&#93;</a></sup>  Potential actions to improve and expand this R&amp;D capacity have been recommended including expansion of human capital, increased private investment, knowledge and patent sharing, infrastructure building for business incubation and innovation support.\n</p>\n<h3><span class=\"mw-headline\" id=\"Innovation_prizes_and_grants\">Innovation prizes and grants</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=Neglected_tropical_disease_research_and_development&amp;action=edit&amp;section=7\" title=\"Edit section: Innovation prizes and grants\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h3>\n<p>Competitive innovation prizes have been used to spur development in a range of fields such as aerospace engineering, clean technology, and genomics. The <a href=\"/wiki/X-Prize_Foundation\" class=\"mw-redirect\" title=\"X-Prize Foundation\">X-Prize Foundation</a> is launching a competition for high speed, point-of-care diagnostics for tuberculosis.<sup class=\"noprint Inline-Template Template-Fact\" style=\"white-space:nowrap;\">&#91;<i><a href=\"/wiki/Wikipedia:Citation_needed\" title=\"Wikipedia:Citation needed\"><span title=\"This claim needs references to reliable sources. (June 2012)\">citation needed</span></a></i>&#93;</sup> A more widely defined annual \"Global Health EnterPrize\" for neglected tropical diseases has been proposed to reward health innovators, particularly those based in countries where NTDs represent a serious health burden.<sup class=\"noprint Inline-Template Template-Fact\" style=\"white-space:nowrap;\">&#91;<i><a href=\"/wiki/Wikipedia:Citation_needed\" title=\"Wikipedia:Citation needed\"><span title=\"This claim needs references to reliable sources. (June 2012)\">citation needed</span></a></i>&#93;</sup>\n</p><p>The <a href=\"/wiki/Bill_%26_Melinda_Gates_Foundation\" title=\"Bill &amp; Melinda Gates Foundation\">Bill &amp; Melinda Gates Foundation</a> offers the Grand Challenges Explorations Opportunities on a rolling basis. This grant program allows individuals from any organization or background to apply to address priority global health issues. Each project award is $100,000 dollars and is drawn from a Foundation funding pool of $100 million. Awardees have tended to offer research projects on topics that are highly speculative but offer potentially game-changing breakthroughs in global health.\n</p>\n<h3><span id=\"FDA_priority_review_vouchers_.28PRV.29\"></span><span class=\"mw-headline\" id=\"FDA_priority_review_vouchers_(PRV)\">FDA priority review vouchers (PRV)</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=Neglected_tropical_disease_research_and_development&amp;action=edit&amp;section=8\" title=\"Edit section: FDA priority review vouchers (PRV)\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h3>\n<p>In 2006, Ridley <i>et al</i> recommended the development of a <a href=\"/wiki/Priority_review_voucher\" class=\"mw-redirect\" title=\"Priority review voucher\">priority review voucher</a> (PRV) in the journal <i><a href=\"/wiki/Health_Affairs\" title=\"Health Affairs\">Health Affairs</a></i>.  It gained interest by Senator <a href=\"/wiki/Sam_Brownback\" title=\"Sam Brownback\">Sam Brownback</a> of Kansas who championed its introduction in the <a href=\"/wiki/Food_and_Drug_Administration_Amendments_Act_of_2007\" title=\"Food and Drug Administration Amendments Act of 2007\">FDA Amendments Act of 2007</a>.  Under the enacted law, FDA approval of a non-NTD drug can be accelerated through the drug review process if paired to a drug that addresses a NTD.  The potential economic benefit to a pharmaceutical company is estimated to be potentially as high as $300 million per drug.  Three drugs have earned NTD PRVs to date (December 2014): Coartem (by Novartis, for malaria); bedaquiline (by Janssen, for TB) and miltefosine (by Knight, for leishmaniasis).  However, the success of the PRV system is now under much scrutiny, given that Knight benefitted by $125 million from the sale of a PRV earned from a drug (miltefosine) that was largely researched and developed by the WHO.  Medicins San Frontiers are now pressuring Knight to guarantee supplying miltefosine at cost price, thus far without success.\n</p><p>The PRV isn't limited to the pairing of drugs within a single company, rather can be transferred between companies.  Companies with NTD drug candidates in their pipelines but without a blockbuster drug, are able to sell their voucher producing financial returns. In the EU, similar priority review incentives are now under consideration to increase the speed of regulatory pricing and reimbursement decisions.\n</p><p>However, PRVs have been criticized as being open to manipulation and possibly encouraging errors through too rapid regulatory decision-making.<sup id=\"cite_ref-O_24-0\" class=\"reference\"><a href=\"#cite_note-O-24\">&#91;24&#93;</a></sup>\n</p>\n<h3><span class=\"mw-headline\" id=\"Open_source_collaboration_initiatives\">Open source collaboration initiatives</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=Neglected_tropical_disease_research_and_development&amp;action=edit&amp;section=9\" title=\"Edit section: Open source collaboration initiatives\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h3>\n<div class=\"thumb tright\"><div class=\"thumbinner\" style=\"width:222px;\"><a href=\"/wiki/File:DNDi_logo.JPG\" class=\"image\"><img alt=\"\" src=\"//upload.wikimedia.org/wikipedia/commons/thumb/7/74/DNDi_logo.JPG/220px-DNDi_logo.JPG\" width=\"220\" height=\"61\" class=\"thumbimage\" srcset=\"//upload.wikimedia.org/wikipedia/commons/thumb/7/74/DNDi_logo.JPG/330px-DNDi_logo.JPG 1.5x, //upload.wikimedia.org/wikipedia/commons/thumb/7/74/DNDi_logo.JPG/440px-DNDi_logo.JPG 2x\" data-file-width=\"960\" data-file-height=\"264\" /></a>  <div class=\"thumbcaption\"><div class=\"magnify\"><a href=\"/wiki/File:DNDi_logo.JPG\" class=\"internal\" title=\"Enlarge\"></a></div>The Drugs for Neglected Diseases Initiative, a web focused not-for-profit drug R&amp;D organization dedicated to creating new NTD treatments.</div></div></div><p>Several companies and scientific organizations are participating in open source initiatives to share drug data and patent information over the web, and facilitate virtual collaboration on NTD research.\n</p><p>One rich area to explore is in the wealth of genomic data resulting from the sequencing of parasite genomes.  These data offer opportunities for the exploration of new therapeutic products using computational, and <a href=\"/wiki/Open_source\" class=\"mw-redirect\" title=\"Open source\">open source</a> collaboration methods for drug discovery.<sup id=\"cite_ref-M_25-0\" class=\"reference\"><a href=\"#cite_note-M-25\">&#91;25&#93;</a></sup><sup id=\"cite_ref-N_26-0\" class=\"reference\"><a href=\"#cite_note-N-26\">&#91;26&#93;</a></sup> The Tropical Disease Initiative, for example, has used large amounts of computing power to generate the protein structures for ten parasite genomes.  An open source drug bank was matched algorithmically to determine compounds with protein interaction activity, and two candidates were identified.  In general, such methods may hold important opportunities for <a href=\"/wiki/Off-label_use\" title=\"Off-label use\">off-label use</a> of existing approved drugs.\n</p>\n<h2><span class=\"mw-headline\" id=\"References\">References</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=Neglected_tropical_disease_research_and_development&amp;action=edit&amp;section=10\" title=\"Edit section: References\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h2>\n<div class=\"reflist columns references-column-width\" style=\"-moz-column-width: 30em; -webkit-column-width: 30em; column-width: 30em; list-style-type: decimal;\">\n<ol class=\"references\">\n<li id=\"cite_note-I-1\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-I_1-0\">^</a></b></span> <span class=\"reference-text\">Feasey N, Wansbrough-Jones M, Mabey DC, Solomon AW. Neglected tropical diseases. <i>Br Med Bull.</i> 2010;93:179-200. Epub 2009 Dec 10. Review.</span>\n</li>\n<li id=\"cite_note-K2-2\"><span class=\"mw-cite-backlink\">^ <a href=\"#cite_ref-K2_2-0\"><sup><i><b>a</b></i></sup></a> <a href=\"#cite_ref-K2_2-1\"><sup><i><b>b</b></i></sup></a></span> <span class=\"reference-text\">Hotez PJ, Molyneux DH, Fenwick A, Ottesen E, Ehrlich Sachs S, Sachs JD. Incorporating a rapid-impact package for neglected tropical diseases with programs for HIV/AIDS, tuberculosis, and malaria. <i>PLoS Med</i> 2006 Jan;3(5):e102.</span>\n</li>\n<li id=\"cite_note-K-3\"><span class=\"mw-cite-backlink\">^ <a href=\"#cite_ref-K_3-0\"><sup><i><b>a</b></i></sup></a> <a href=\"#cite_ref-K_3-1\"><sup><i><b>b</b></i></sup></a> <a href=\"#cite_ref-K_3-2\"><sup><i><b>c</b></i></sup></a> <a href=\"#cite_ref-K_3-3\"><sup><i><b>d</b></i></sup></a> <a href=\"#cite_ref-K_3-4\"><sup><i><b>e</b></i></sup></a></span> <span class=\"reference-text\">Hotez PJ, Molyneux DH, Fenwick A, Kumaresan J, Sachs SE, Sachs JD, et al. Control of neglected tropical diseases. <i>N Engl J Med</i> 2007 Sep 6;357(10):1018-1027.</span>\n</li>\n<li id=\"cite_note-G-4\"><span class=\"mw-cite-backlink\">^ <a href=\"#cite_ref-G_4-0\"><sup><i><b>a</b></i></sup></a> <a href=\"#cite_ref-G_4-1\"><sup><i><b>b</b></i></sup></a></span> <span class=\"reference-text\">Conteh L, Engels T, Molyneux DH. Socioeconomic aspects of neglected tropical diseases. <i>Lancet</i> 2010 Jan 16;375(9710):239-247.</span>\n</li>\n<li id=\"cite_note-L-5\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-L_5-0\">^</a></b></span> <span class=\"reference-text\">Hotez P, Ottesen E, Fenwick A, Molyneux D. The neglected tropical diseases: the ancient afflictions of stigma and poverty and the prospects for their control and elimination. <i>Adv Exp Med Biol</i> 2006;582:23-33.</span>\n</li>\n<li id=\"cite_note-T-6\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-T_6-0\">^</a></b></span> <span class=\"reference-text\">Reddy M, Gill SS, Kalkar SR, Wu W, Anderson PJ, Rochon PA. Oral drug therapy for multiple neglected tropical diseases: a systematic review. <i>JAMA</i> 2007 Oct 24;298(16):1911-1924.</span>\n</li>\n<li id=\"cite_note-Y-7\"><span class=\"mw-cite-backlink\">^ <a href=\"#cite_ref-Y_7-0\"><sup><i><b>a</b></i></sup></a> <a href=\"#cite_ref-Y_7-1\"><sup><i><b>b</b></i></sup></a> <a href=\"#cite_ref-Y_7-2\"><sup><i><b>c</b></i></sup></a></span> <span class=\"reference-text\">Trouiller P, Olliaro P, Torreele E, Orbinski J, Laing R, Ford N. Drug development for neglected diseases: a deficient market and a public-health policy failure. <i>Lancet</i> 2002 Jun 22;359(9324):2188-2194.</span>\n</li>\n<li id=\"cite_note-E-8\"><span class=\"mw-cite-backlink\">^ <a href=\"#cite_ref-E_8-0\"><sup><i><b>a</b></i></sup></a> <a href=\"#cite_ref-E_8-1\"><sup><i><b>b</b></i></sup></a> <a href=\"#cite_ref-E_8-2\"><sup><i><b>c</b></i></sup></a> <a href=\"#cite_ref-E_8-3\"><sup><i><b>d</b></i></sup></a></span> <span class=\"reference-text\">Cohen J, Dibner MS, Wilson A. Development of and access to products for neglected diseases. <i>PLoS One</i> 2010 May 12;5(5):e10610.</span>\n</li>\n<li id=\"cite_note-D3-9\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-D3_9-0\">^</a></b></span> <span class=\"reference-text\">Chu BK, Hooper PJ, Bradley MH, McFarland DA, Ottesen EA. The economic benefits resulting from the first 8 years of the Global Programme to Eliminate Lymphatic Filariasis (2000-2007). PLoS Negl Trop Dis. 2010 Jun 1;4(6):e708.</span>\n</li>\n<li id=\"cite_note-D4-10\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-D4_10-0\">^</a></b></span> <span class=\"reference-text\">Merck Mectizan Drug Donation Program <a rel=\"nofollow\" class=\"external free\" href=\"http://www.mectizan.org/\">http://www.mectizan.org/</a></span>\n</li>\n<li id=\"cite_note-Z2-11\"><span class=\"mw-cite-backlink\">^ <a href=\"#cite_ref-Z2_11-0\"><sup><i><b>a</b></i></sup></a> <a href=\"#cite_ref-Z2_11-1\"><sup><i><b>b</b></i></sup></a> <a href=\"#cite_ref-Z2_11-2\"><sup><i><b>c</b></i></sup></a></span> <span class=\"reference-text\">Villa S, Compagni A, Reich MR. Orphan drug legislation: lessons for neglected tropical diseases. <i>Int J Health Plann Manage</i> 2009 Jan-Mar;24(1):27-42.</span>\n</li>\n<li id=\"cite_note-Z-12\"><span class=\"mw-cite-backlink\">^ <a href=\"#cite_ref-Z_12-0\"><sup><i><b>a</b></i></sup></a> <a href=\"#cite_ref-Z_12-1\"><sup><i><b>b</b></i></sup></a> <a href=\"#cite_ref-Z_12-2\"><sup><i><b>c</b></i></sup></a> <a href=\"#cite_ref-Z_12-3\"><sup><i><b>d</b></i></sup></a></span> <span class=\"reference-text\">Trouiller P, Torreele E, Olliaro P, White N, Foster S, Wirth D, et al. Drugs for neglected diseases: a failure of the market and a public health failure? <i>Trop Med Int Health</i> 2001 Nov;6(11):945-951.</span>\n</li>\n<li id=\"cite_note-D2-13\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-D2_13-0\">^</a></b></span> <span class=\"reference-text\">Chirac P, Torreele E. Global framework on essential health R&amp;D. Lancet. 2006 May 13;367(9522):1560-1.</span>\n</li>\n<li id=\"cite_note-A-14\"><span class=\"mw-cite-backlink\">^ <a href=\"#cite_ref-A_14-0\"><sup><i><b>a</b></i></sup></a> <a href=\"#cite_ref-A_14-1\"><sup><i><b>b</b></i></sup></a> <a href=\"#cite_ref-A_14-2\"><sup><i><b>c</b></i></sup></a></span> <span class=\"reference-text\">Bethony JM, Cole RN, Guo X, Kamhawi S, Lightowlers MW, Loukas A, et al. Vaccines to combat the neglected tropical diseases. <i>Immunol Rev</i> 2011 Jan;239(1):237-270.</span>\n</li>\n<li id=\"cite_note-Q-15\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-Q_15-0\">^</a></b></span> <span class=\"reference-text\">Liese B, Rosenberg M, Schratz A. Programmes, partnerships, and governance for elimination and control of neglected tropical diseases. <i>Lancet</i> 2010 Jan 2;375(9708):67-76.</span>\n</li>\n<li id=\"cite_note-Z3-16\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-Z3_16-0\">^</a></b></span> <span class=\"reference-text\">World Health Organization. Working to overcome the global impact of neglected tropical diseases: first WHO report on neglected tropical diseases. 2010.</span>\n</li>\n<li id=\"cite_note-Z4-17\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-Z4_17-0\">^</a></b></span> <span class=\"reference-text\">G-FINDER Database <a rel=\"nofollow\" class=\"external free\" href=\"http://www.georgeinstitute.org/about-us/media-centre/g-finder-database-open-public\">http://www.georgeinstitute.org/about-us/media-centre/g-finder-database-open-public</a></span>\n</li>\n<li id=\"cite_note-A2-18\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-A2_18-0\">^</a></b></span> <span class=\"reference-text\">Adams CP, Brantner VV. Estimating the cost of new drug development: is it really 802 million dollars?  Health Aff (Millwood). 2006 Mar-Apr;25(2):420-8.</span>\n</li>\n<li id=\"cite_note-A1-19\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-A1_19-0\">^</a></b></span> <span class=\"reference-text\">DiMasi JA, Hansen RW, Grabowski HG. The price of innovation: new estimates of drug development costs.  J Health Econ. 2003 Mar;22(2):151-85.</span>\n</li>\n<li id=\"cite_note-X-20\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-X_20-0\">^</a></b></span> <span class=\"reference-text\">Tchuem Tchuente LA. Control of soil-transmitted helminths in sub-Saharan Africa: Diagnosis, drug efficacy concerns and challenges. <i>Acta Trop</i> 2010 Jul 21.</span>\n</li>\n<li id=\"cite_note-V-21\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-V_21-0\">^</a></b></span> <span class=\"reference-text\">Smits HL. Prospects for the control of neglected tropical diseases by mass drug administration. <i>Expert Rev Anti Infect Ther</i> 2009 Feb;7(1):37-56.</span>\n</li>\n<li id=\"cite_note-U-22\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-U_22-0\">^</a></b></span> <span class=\"reference-text\">Renslo AR, McKerrow JH. Drug discovery and development for neglected parasitic diseases. <i>Nat Chem Biol</i> 2006 Dec;2(12):701-710.</span>\n</li>\n<li id=\"cite_note-J-23\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-J_23-0\">^</a></b></span> <span class=\"reference-text\">Frew SE, Liu VY, Singer PA. A business plan to help the 'global South' in its fight against neglected diseases. <i>Health Aff</i> (Millwood) 2009 Nov-Dec;28(6):1760-1773.</span>\n</li>\n<li id=\"cite_note-O-24\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-O_24-0\">^</a></b></span> <span class=\"reference-text\">Kesselheim AS. Drug development for neglected diseases - the trouble with FDA review vouchers. <i>N Engl J Med</i> 2008 Nov 6;359(19):1981-1983.</span>\n</li>\n<li id=\"cite_note-M-25\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-M_25-0\">^</a></b></span> <span class=\"reference-text\">Kar S. Opinion: Open innovation: an answer for neglected diseases. <i>Future Med Chem</i> 2010 Sep;2(9):1411-5.</span>\n</li>\n<li id=\"cite_note-N-26\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-N_26-0\">^</a></b></span> <span class=\"reference-text\">Ort\u00ed L, Carbajo RJ, Pieper U, Eswar N, Maurer SM, Rai AK, Taylor G, Todd MH, Pineda-Lucena A, Sali A, Marti-Renom MA. A kernel for open source drug discovery in tropical diseases. <i>PLoS Negl Trop Dis</i> 2009;3(4):e418.</span>\n</li>\n</ol></div>\n<h2><span class=\"mw-headline\" id=\"Further_reading\">Further reading</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=Neglected_tropical_disease_research_and_development&amp;action=edit&amp;section=11\" title=\"Edit section: Further reading\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h2>\n<ul><li>Progress and challenges in neglected tropical diseases. <i>Lancet</i> 2010 Oct 23;376(9750):1363.</li>\n<li>Remembering the neglected tropical diseases. <i>Lancet</i> 2007 Dec 8;370(9603):1880.</li>\n<li>WHO and Sanofi-Aventis expand programme to fight neglected tropical diseases. <i>Indian J Med Sci</i> 2006 Nov;60(11):487.</li>\n<li>Research versus treatment for neglected diseases. <i>Lancet</i> 2006 Feb 11;367(9509):448.</li>\n<li>Aksoy S. Solutions to neglected tropical diseases require vibrant local scientific communities. <i>PLoS Negl Trop Dis</i> 2010 Mar 30;4(3):e662.</li>\n<li>Allotey P, Reidpath DD, Pokhrel S. Social sciences research in neglected tropical diseases: the ongoing neglect in the neglected tropical diseases. <i>Health Res Policy Syst</i> 2010 Oct 21;8:32.</li>\n<li>Alvar J, Yactayo S, Bern C. Leishmaniasis and poverty. <i>Trends Parasitol</i> 2006 Dec;22(12):552-557.</li>\n<li>Ameen M. Cutaneous leishmaniasis: therapeutic strategies and future directions. <i>Expert Opin Pharmacother</i> 2007 Nov;8(16):2689-2699.</li>\n<li>Ault SK. Intersectoral approaches to neglected diseases. <i>Ann N Y Acad Sci</i> 2008;1136:64-69.</li>\n<li>Ault SK, Nicholls RS. Integrated approach to neglected tropical diseases in Latin America and the Caribbean: an ethical imperative to reach justice and social equity. <i>Biomedica</i> 2010 Jun;30(2):159-163.</li>\n<li>Baker MC, Mathieu E, Fleming FM, Deming M, King JD, Garba A, et al. Mapping, monitoring, and surveillance of neglected tropical diseases: towards a policy framework. <i>Lancet</i> 2010 Jan 16;375(9710):231-238.</li>\n<li>Bethony JM, Diemert DJ, Oliveira SC, Loukas A. Can schistosomiasis really be consigned to history without a vaccine? <i>Vaccine</i> 2008 Jun 25;26(27-28):3373-3376.</li>\n<li>Bitran R, Martorell B, Escobar L, Munoz R, Glassman A. Controlling and eliminating neglected diseases in Latin America and the Caribbean. <i>Health Aff</i> (Millwood) 2009 Nov-Dec;28(6):1707-1719.</li>\n<li>Bockarie MJ, Deb RM. Elimination of lymphatic filariasis: do we have the drugs to complete the job? <i>Curr Opin Infect Dis</i> 2010 Dec;23(6):617-620.</li>\n<li>Bockarie MJ, Pedersen EM, White GB, Michael E. Role of vector control in the global program to eliminate lymphatic filariasis. <i>Annu Rev Entomol</i> 2009;54:469-487.</li>\n<li>Boelaert M, Meheus F, Robays J, Lutumba P. Socio-economic aspects of neglected diseases: sleeping sickness and visceral leishmaniasis. <i>Ann Trop Med Parasitol</i> 2010 Oct;104(7):535-542.</li>\n<li>Bottazzi ME, Brown AS. Model for product development of vaccines against neglected tropical diseases: a vaccine against human hookworm. <i>Expert Rev Vaccines</i> 2008 Dec;7(10):1481-1492.</li>\n<li>Bottazzi ME, Miles AP, Diemert D, Hotez PJ. An ounce of prevention on a budget: a nonprofit approach to developing vaccines against neglected diseases. <i>Expert Rev Vaccines</i> 2006 Apr;5(2):189-198.</li>\n<li>Brady MA, Hooper PJ, Ottesen EA. Projected benefits from integrating NTD programs in sub-Saharan Africa. <i>Trends Parasitol</i> 2006 Jul;22(7):285-291.</li>\n<li>Brownback S. Eliminating neglected diseases: impact of published paper. <i>Health Aff</i> (Millwood) 2007 Sep-Oct;26(5):1509.</li>\n<li>Butler D. Neglected disease boost. <i>Nature</i> 2009 Feb 12;457(7231):772-773.</li>\n<li>Canning D. Priority setting and the 'neglected' tropical diseases. <i>Trans R Soc Trop Med Hyg</i> 2006 Jun;100(6):499-504.</li>\n<li>Cavalli A, Bamba SI, Traore MN, Boelaert M, Coulibaly Y, Polman K, et al. Interactions between Global Health Initiatives and country health systems: the case of a neglected tropical diseases control program in Mali. <i>PLoS Negl Trop Dis</i> 2010 Aug 17;4(8):e798.</li>\n<li>Chaves LF, Pascual M. Comparing models for early warning systems of neglected tropical diseases. <i>PLoS Negl Trop Dis</i> 2007 Oct 22;1(1):e33.</li>\n<li>Croft SL. Public-private partnership: from there to here. <i>Trans R Soc Trop Med Hyg</i> 2005 Oct;99 Suppl 1:S9-14.</li>\n<li>Crowther GJ, Shanmugam D, Carmona SJ, Doyle MA, Hertz-Fowler C, Berriman M, et al. Identification of attractive drug targets in neglected-disease pathogens using an in silico approach. <i>PLoS Negl Trop Dis</i> 2010 Aug 24;4(8):e804.</li>\n<li>Dantas-Torres F, Marcondes CB. Fighting neglected tropical diseases in the postgenomic era. <i>Trends Parasitol</i> 2008 Apr;24(4):156-7; author reply 157-8.</li>\n<li>Denery JR, Nunes AA, Hixon MS, Dickerson TJ, Janda KD. Metabolomics-based discovery of diagnostic biomarkers for onchocerciasis. <i>PLoS Negl Trop Dis</i> 2010 Oct 5;4(10):e834.</li>\n<li>Dybul M. Neglected tropical diseases and HIV/AIDS. <i>Lancet</i> 2006 Nov 25;368(9550):1865.</li>\n<li>Ebrahim GJ. Neglected tropical diseases. <i>J Trop Pediatr</i> 2009 Jun;55(3):141-144.</li>\n<li>Engels D, Savioli L. Reconsidering the underestimated burden caused by neglected tropical diseases. <i>Trends Parasitol</i> 2006 Aug;22(8):363-366.</li>\n<li>Fenwick A, Webster JP, Bosque-Oliva E, Blair L, Fleming FM, Zhang Y, et al. The Schistosomiasis Control Initiative (SCI): rationale, development and implementation from 2002-2008. <i>Parasitology</i> 2009 Nov;136(13):1719-1730.</li>\n<li>Frearson J, Wyatt P. Drug Discovery in Academia- the third way? <i>Expert Opin Drug Discov</i> 2010 Oct 1;5(10):909-919.</li>\n<li>Frezard F, Demicheli C. New delivery strategies for the old pentavalent antimonial drugs. <i>Expert Opin Drug Deliv</i> 2010 Dec;7(12):1343-1358.</li>\n<li>Germani Y, Sansonetti P. \"Neglected diseases\": it is better to respond to future challenges\u2014the model of a pilot North-South program on enteric infections integrating many research components. <i>C R Biol</i> 2008 Dec;331(12):973-981.</li>\n<li>Gloeckner C, Garner AL, Mersha F, Oksov Y, Tricoche N, Eubanks LM, et al. Repositioning of an existing drug for the neglected tropical disease Onchocerciasis. <i>Proc Natl Acad Sci USA</i> 2010 Feb 23;107(8):3424-3429.</li>\n<li>Gray DJ, Forsyth SJ, Li RS, McManus DP, Li Y, Chen H, et al. An innovative database for epidemiological field studies of neglected tropical diseases. <i>PLoS Negl Trop Dis</i> 2009 May 26;3(5):e413.</li>\n<li>Gray DJ, McManus DP, Li Y, Williams GM, Bergquist R, Ross AG. Schistosomiasis elimination: lessons from the past guide the future. <i>Lancet Infect Dis</i> 2010 Oct;10(10):733-736.</li>\n<li>Grepin KA, Reich MR. Conceptualizing integration: a framework for analysis applied to neglected tropical disease control partnerships. <i>PLoS Negl Trop Dis</i> 2008 Apr 30;2(4):e174.</li>\n<li>Gustavsen K, Hanson C. Progress in public-private partnerships to fight neglected diseases. <i>Health Aff</i> (Millwood) 2009 Nov-Dec;28(6):1745-1749.</li>\n<li>Gyapong JO, Gyapong M, Yellu N, Anakwah K, Amofah G, Bockarie M, et al. Integration of control of neglected tropical diseases into health-care systems: challenges and opportunities. <i>Lancet</i> 2010 Jan 9;375(9709):160-165.</li>\n<li>Hanvoravongchai P, Warakamin B, Coker R. Critical interactions between Global Fund-supported programmes and health systems: a case study in Thailand. <i>Health Policy Plan</i> 2010 Nov;25 Suppl 1:i53-57.</li>\n<li>Hopkins AD. Challenges for the integration of mass drug administrations against multiple 'neglected tropical diseases'. <i>Ann Trop Med Parasitol</i> 2009 Oct;103 Suppl 1:S23-31.</li>\n<li>Hotez P. A national school of tropical medicine and neglected infections of poverty for North America. <i>PLoS Negl Trop Dis</i> 2010 Jun 29;4(6):e735.</li>\n<li>Hotez P. Neglected diseases amid wealth in the United States and Europe. <i>Health Aff</i> (Millwood) 2009 Nov-Dec;28(6):1720-1725.</li>\n<li>Hotez P, Raff S, Fenwick A, Richards F,Jr, Molyneux DH. Recent progress in integrated neglected tropical disease control. <i>Trends Parasitol</i> 2007 Nov;23(11):511-514.</li>\n<li>Hotez PJ. Neglected tropical disease control in the \"post-American world\". <i>PLoS Negl Trop Dis</i> 2010 Aug 31;4(8):e812.</li>\n<li>Hotez PJ. A plan to defeat neglected tropical diseases. <i>Sci Am</i> 2010 Jan;302(1):90-4, 96.</li>\n<li>Hotez PJ. One world health: neglected tropical diseases in a flat world. <i>PLoS Negl Trop Dis</i> 2009;3(4):e405.</li>\n<li>Hotez PJ. Mass drug administration and integrated control for the world's high-prevalence neglected tropical diseases. <i>Clin Pharmacol Ther</i> 2009 Jun;85(6):659-664.</li>\n<li>Hotez PJ. Neglected infections of poverty in the United States of America. <i>PLoS Negl Trop Dis</i> 2008 Jun 25;2(6):e256.</li>\n<li>Hotez PJ. The giant anteater in the room: Brazil's neglected tropical diseases problem. <i>PLoS Negl Trop Dis</i> 2008 Jan 30;2(1):e177.</li>\n<li>Hotez PJ. Reinventing Guantanamo: from detainee facility to Center for Research on Neglected Diseases of Poverty in the Americas. <i>PLoS Negl Trop Dis</i> 2008 Feb 27;2(2):e201.</li>\n<li>Hotez PJ, Bethony J, Bottazzi ME, Brooker S, Diemert D, Loukas A. New technologies for the control of human hookworm infection. <i>Trends Parasitol</i> 2006 Jul;22(7):327-331.</li>\n<li>Hotez PJ, Brindley PJ, Bethony JM, King CH, Pearce EJ, Jacobson J. Helminth infections: the great neglected tropical diseases. <i>J Clin Invest</i> 2008 Apr;118(4):1311-1321.</li>\n<li>Hotez PJ, Brown AS. Neglected tropical disease vaccines. <i>Biologicals</i> 2009 Jun;37(3):160-164.</li>\n<li>Hotez PJ, Ehrenberg JP. Escalating the global fight against neglected tropical diseases through interventions in the Asia Pacific region. <i>Adv Parasitol</i> 2010;72:31-53.</li>\n<li>Hotez PJ, Fenwick A, Savioli L, Molyneux DH. Rescuing the bottom billion through control of neglected tropical diseases. <i>Lancet</i> 2009 May 2;373(9674):1570-1575.</li>\n<li>Hotez PJ, Ferris MT. The antipoverty vaccines. <i>Vaccine</i> 2006 Jul 26;24(31-32):5787-5799.</li>\n<li>Hotez PJ, Molyneux DH, Fenwick A, Savioli L, Takeuchi T. A Global Fund to Fight Neglected Tropical Diseases: is the G8 Hokkaido Toyako 2008 Summit ready? <i>PLoS Negl Trop Dis</i> 2008 Mar 26;2(3):e220.</li>\n<li>Hotez PJ, Molyneux DH, Stillwaggon E, Bentwich Z, Kumaresan J. Neglected tropical diseases and HIV/AIDS. <i>Lancet</i> 2006 Nov 25;368(9550):1865-1866.</li>\n<li>Hotez PJ, Pecoul B. \"Manifesto\" for advancing the control and elimination of neglected tropical diseases. <i>PLoS Negl Trop Dis</i> 2010 May 25;4(5):e718.</li>\n<li>Hotez PJ, Thompson TG. Waging peace through neglected tropical disease control: a US foreign policy for the bottom billion. <i>PLoS Negl Trop Dis</i> 2009;3(1):e346.</li>\n<li>Hunter PR. Bibliometrics, research quality, and neglected tropical diseases. <i>Lancet</i> 2009 Feb 21;373(9664):630-631.</li>\n<li>Huppatz C, Durrheim DN. Control of neglected tropical diseases. <i>N Engl J Med</i> 2007 Dec 6;357(23):2407; author reply 2407-8.</li>\n<li>John JE,  Pharma Research for Tropical Diseases, Current Science, vol 91(9), page 1127, 10 November 2006, Bangalore (Indian Academy of  Sciences), India.</li>\n<li>John JE, Anti-Infective Agents: Spectrum and Selectivity, Current Science, vol 92(2), page 159, 25th Jan 2007, Bangalore (Indian Academy of Sciences), India.</li>\n<li>John JE, Tropical diseases research and anti-fungal research linked with cancer research, Current Science, 2009, 25th Dec, 97(12), 1704.</li>\n<li>John JE, Medicines for tropical diseases; support through tax-incentives, Drug Discovery Today, 2011, volume 16 (3/4), 91\u201392.</li>\n<li>Kabatereine N. The unsung hero of neglected tropical diseases: interview with Narcis Kabatereine by Gavin Yamey. <i>PLoS Negl Trop Dis</i> 2009 Dec 22;3(12):e546.</li>\n<li>Kabatereine NB, Malecela M, Lado M, Zaramba S, Amiel O, Kolaczinski JH. How to (or not to) integrate vertical programmes for the control of major neglected tropical diseases in sub-Saharan Africa. <i>PLoS Negl Trop Dis</i> 2010 Jun 29;4(6):e755.</li>\n<li>Kettler HE, Modi R. Building local research and development capacity for the prevention and cure of neglected diseases: the case of India. <i>Bull World Health Organ</i> 2001;79(8):742-747.</li>\n<li>King CH, Bertino AM. Asymmetries of poverty: why global burden of disease valuations underestimate the burden of neglected tropical diseases. <i>PLoS Negl Trop Dis</i> 2008 Mar 26;2(3):e209.</li>\n<li>Kuepfer I, Burri C. Reflections on clinical research in sub-Saharan Africa. <i>Int J Parasitol</i> 2009 Jul 15;39(9):947-954.</li>\n<li>Kuhn I, Kellenberger E, Said-Hassane F, Villa P, Rognan D, Lobstein A, et al. Identification by high-throughput screening of inhibitors of Schistosomamansoni NAD(+) catabolizing enzyme. <i>Bioorg Med Chem</i> 2010 Nov 15;18(22):7900-7910.</li>\n<li>Mahmoud A, Zerhouni E. Neglected tropical diseases: moving beyond mass drug treatment to understanding the science. <i>Health Aff</i> (Millwood) 2009 Nov-Dec;28(6):1726-1733.</li>\n<li>Maltezou HC. Drug resistance in visceral leishmaniasis. <i>J Biomed Biotechnol</i> 2010;2010:617521.</li>\n<li>Mathers CD, Ezzati M, Lopez AD. Measuring the burden of neglected tropical diseases: the global burden of disease framework. <i>PLoS Negl Trop Dis</i> 2007 Nov 7;1(2):e114.</li>\n<li>Matter A, Keller TH. Impact of non-profit organizations on drug discovery: opportunities, gaps, solutions. <i>Drug Discov Today</i> 2008 Apr;13(7-8):347-352.</li>\n<li>May RM. Parasites, people and policy: infectious diseases and the Millennium Development Goals. <i>Trends Ecol Evol</i> 2007 Oct;22(10):497-503.</li>\n<li>Millet P. Status of research and development for control of tropical diseases: hypocrisy, indifference or lack of coordination. <i>Med Trop</i> (Mars) 2006 Dec;66(6):542-548.</li>\n<li>Molyneux DH. Neglected tropical diseases\u2014beyond the tipping point? <i>Lancet</i> 2010 Jan 2;375(9708):3-4.</li>\n<li>Molyneux DH. \"Neglected\" diseases but unrecognised successes\u2014challenges and opportunities for infectious disease control. <i>Lancet</i> 2004 Jul 24-30;364(9431):380-383.</li>\n<li>Molyneux DH, Hotez PJ, Fenwick A. \"Rapid-impact interventions\": how a policy of integrated control for Africa's neglected tropical diseases could benefit the poor. <i>PLoS Med</i> 2005 Nov;2(11):e336.</li>\n<li>Molyneux DH, Hotez PJ, Fenwick A, Newman RD, Greenwood B, Sachs J. Neglected tropical diseases and the Global Fund. <i>Lancet</i> 2009 Jan 24;373(9660):296-297.</li>\n<li>Morel CM. Neglected diseases: under-funded research and inadequate health interventions. Can we change this reality? <i>EMBO Rep</i> 2003 Jun;4 Spec No:S35-8.</li>\n<li>Morel CM, Serruya SJ, Penna GO, Guimaraes R. Co-authorship network analysis: a powerful tool for strategic planning of research, development and capacity building programs on neglected diseases. <i>PLoS Negl Trop Dis</i> 2009 Aug 18;3(8):e501.</li>\n<li>Morris K. Time to overcome the neglect of neglected tropical diseases. <i>Lancet Infect Dis</i> 2010 Dec;10(12):820-821.</li>\n<li>Muela Ribera J, Peeters Grietens K, Toomer E, Hausmann-Muela S. A word of caution against the stigma trend in neglected tropical disease research and control. <i>PLoS Negl Trop Dis</i> 2009 Oct 27;3(10):e445.</li>\n<li>Musgrove P, Hotez PJ. Turning neglected tropical diseases into forgotten maladies. <i>Health Aff</i> (Millwood) 2009 Nov-Dec;28(6):1691-1706.</li>\n<li>Narain JP, Dash AP, Parnell B, Bhattacharya SK, Barua S, Bhatia R, et al. Elimination of neglected tropical diseases in the South-East Asia Region of the World Health Organization. <i>Bull World Health Organ</i> 2010 Mar;88(3):206-210.</li>\n<li>Nelson K. Stimulating research in the most neglected diseases. <i>Lancet</i> 2002 Mar 23;359(9311):1042.</li>\n<li>Nickerson EK, West TE, Day NP, Peacock SJ. Staphylococcus aureus disease and drug resistance in resource-limited countries in south and east Asia. <i>Lancet Infect Dis</i> 2009 Feb;9(2):130-135.</li>\n<li>Nkengasong JN, Nsubuga P, Nwanyanwu O, Gershy-Damet GM, Roscigno G, Bulterys M, et al. Laboratory systems and services are critical in global health: time to end the neglect? <i>Am J Clin Pathol</i> 2010 Sep;134(3):368-373.</li>\n<li>Norman FF, Perez de Ayala A, Perez-Molina JA, Monge-Maillo B, Zamarron P, Lopez-Velez R. Neglected tropical diseases outside the tropics. <i>PLoS Negl Trop Dis</i> 2010 Jul 27;4(7):e762.</li>\n<li>Normile D. Singapore. Novartis kicks off institute for neglected diseases. <i>Science</i> 2003 Feb 7;299(5608):811.</li>\n<li>Nwaka S, Ramirez B, Brun R, Maes L, Douglas F, Ridley R. Advancing drug innovation for neglected diseases-criteria for lead progression. <i>PLoS Negl Trop Dis</i> 2009 Aug 25;3(8):e440.</li>\n<li>Olveda R, Leonardo L, Zheng F, Sripa B, Bergquist R, Zhou XN. Coordinating research on neglected parasitic diseases in Southeast Asia through networking. <i>Adv Parasitol</i> 2010;72:55-77.</li>\n<li>Pang T. Vaccines for the prevention of neglected diseases\u2014dengue fever. <i>Curr Opin Biotechnol</i> 2003 Jun;14(3):332-336.</li>\n<li>Parker M, Allen T. Does mass drug administration for the integrated treatment of neglected tropical diseases really work? Assessing evidence for the control of schistosomiasis and soil-transmitted helminths in Uganda. <i>Health Res Policy Syst</i> 2011 Jan 6;9:3.</li>\n<li>Parker M, Allen T, Hastings J. Resisting control of neglected tropical diseases: dilemmas in the mass treatment of schistosomiasis and soil-transmitted helminths in north-west Uganda. <i>J Biosoc Sci</i> 2008 Mar;40(2):161-181.</li>\n<li>Payne L, Fitchett JR. Bringing neglected tropical diseases into the spotlight. <i>Trends Parasitol</i> 2010 Sep;26(9):421-423.</li>\n<li>Pecoul B. New drugs for neglected diseases: from pipeline to patients. <i>PLoS Med</i> 2004 Oct;1(1):e6.</li>\n<li>Pokhrel S, Reidpath D, Allotey P. Social sciences research in neglected tropical diseases: Investment in social science research in neglected diseases of poverty: a case study of Bill and Melinda Gates Foundation. <i>Health Res Policy Syst</i> 2011 Jan 6;9(1):2.</li>\n<li>Remme JH, Blas E, Chitsulo L, Desjeux PM, Engers HD, Kanyok TP, et al. Strategic emphases for tropical diseases research: a TDR perspective. <i>Trends Microbiol</i> 2002 Oct;10(10):435-440.</li>\n<li>Ridley RG, Fletcher ER. Making a difference: 30 years of TDR. <i>Nat Rev Microbiol</i> 2008 May;6(5):401-407.</li>\n<li>Sachs JD. The neglected tropical diseases. <i>Sci Am</i> 2007 Jan;296(1):33A.</li>\n<li>Sakisaka K, Nakamura J. Donors' commitments to neglected tropical diseases: not all bad. <i>Lancet</i> 2010 Mar 13;375(9718):892-893.</li>\n<li>Shotton D, Portwin K, Klyne G, Miles A. Adventures in semantic publishing: exemplar semantic enhancements of a research article. <i>PLoS Comput Biol</i> 2009 Apr;5(4):e1000361.</li>\n<li>Singer BH, Ryff CD. Neglected tropical diseases, neglected data sources, and neglected issues. <i>PLoS Negl Trop Dis</i> 2007 Nov 7;1(2):e104.</li>\n<li>Siqueira-Neto JL, Song OR, Oh H, Sohn JH, Yang G, Nam J, et al. Antileishmanial high-throughput drug screening reveals drug candidates with new scaffolds. <i>PLoS Negl Trop Dis</i> 2010 May 4;4(5):e675.</li>\n<li>Solomon AW, Nayagam S, Pasvol G. Recent advances in tropical medicine. <i>Trans R Soc Trop Med Hyg</i> 2009 Jul;103(7):647-652.</li>\n<li>Sommerfeld J, Oduola AM. Health-related biotechnologies for infectious disease control in Africa: Ethical, Legal and Social Implications (ELSI) of transfer and development. <i>Afr J Med Med Sci</i> 2007;36 Suppl:1-5.</li>\n<li>Stich A, Barrett MP, Krishna S. Waking up to sleeping sickness. <i>Trends Parasitol</i> 2003 May;19(5):195-197.</li>\n<li>Stoever K, Kim A. Global health as a factor in economic and social stability. <i>Health Prog</i> 2007 May-Jun;88(3):57-59.</li>\n<li>Stothard JR, Chitsulo L, Kristensen TK, Utzinger J. Control of schistosomiasis in sub-Saharan Africa: progress made, new opportunities and remaining challenges. <i>Parasitology</i> 2009 Nov;136(13):1665-1675.</li>\n<li>Tanne JH. Collaborations aim to develop new drugs for neglected tropical diseases. <i>BMJ</i> 2009 Jun 29;338:b2638.</li>\n<li>Thylefors B, Alleman MM, Twum-Danso NA. Operational lessons from 20 years of the Mectizan Donation Program for the control of onchocerciasis. <i>Trop Med Int Health</i> 2008 May;13(5):689-696.</li>\n<li>Traynor K. FDA program could boost treatments for neglected diseases. <i>Am J Health Syst Pharm</i> 2008 Sep 1;65(17):1595-1596.</li>\n<li>Tuon FF, Amato VS. Neglected tropical diseases: beyond the wars. <i>Rev Inst Med Trop Sao Paulo</i> 2008 Sep-Oct;50(5):313-314.</li>\n<li>Utzinger J, de Savigny D. Control of neglected tropical diseases: integrated chemotherapy and beyond. <i>PLoS Med</i> 2006 Jan;3(5):e112.</li>\n<li>Utzinger J, N'goran EK, Caffrey CR, Keiser J. From innovation to application: Social-ecological context, diagnostics, drugs and integrated control of schistosomiasis. <i>Acta Trop</i> 2010 Sep 8.</li>\n<li>Vanderelst D, Speybroeck N. Quantifying the lack of scientific interest in neglected tropical diseases. <i>PLoS Negl Trop Dis</i> 2010 Jan 26;4(1):e576.</li>\n<li>Vellay SG, Latimer NE, Paillard G. Interactive text mining with Pipeline Pilot: a bibliographic web-based tool for PubMed. <i>Infect Disord Drug Targets</i> 2009 Jun;9(3):366-374.</li>\n<li>Villafuerte-Galvez J, Curioso WH, Miranda JJ. The role of medical students in the fight to control neglected tropical diseases: a view from Peru. <i>PLoS Negl Trop Dis</i> 2008 Sep 24;2(9):e292.</li>\n<li>Voelker R. Attention sought for neglected diseases. <i>JAMA</i> 2009 May 6;301(17):1755-1756.</li>\n<li>Vogel G. Infectious diseases. Tackling neglected diseases could offer more bang for the buck. <i>Science</i> 2006 Feb 3;311(5761):592-593.</li>\n<li>Walgate R. New non-profit organization will support research to combat neglected diseases. <i>Bull World Health Organ</i> 2002;80(10):842-843.</li>\n<li>Walker D, Fox-Rushby JA. Economic evaluation of communicable disease interventions in developing countries: a critical review of the published literature. <i>Health Econ</i> 2000 Dec;9(8):681-698.</li>\n<li>Waltz E. FDA launches priority vouchers for neglected-disease drugs. <i>Nat Biotechnol</i> 2008 Dec;26(12):1315-1316.</li>\n<li>Weiss MG. Stigma and the social burden of neglected tropical diseases. <i>PLoS Negl Trop</i> Dis 2008 May 14;2(5):e237.</li>\n<li>Witty A. Eliminating neglected diseases in poor countries: a conversation with Andrew Witty. Interview by Susan Dentzer. <i>Health Aff</i> (Millwood) 2009 May-Jun;28(3):w411-6.</li>\n<li>Yamey G, Hotez P. Neglected tropical diseases. <i>BMJ</i> 2007 Aug 11;335(7614):269-270.</li>\n<li>Zarocostas J. Gates foundation pledges new funds to fight neglected diseases. <i>BMJ</i> 2009 Feb 3;338:b454.</li>\n<li>Zhang Y, MacArthur C, Mubila L, Baker S. Control of neglected tropical diseases needs a long-term commitment. <i>BMC Med</i> 2010 Oct 29;8:67.</li></ul>\n<h2><span class=\"mw-headline\" id=\"External_links\">External links</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=Neglected_tropical_disease_research_and_development&amp;action=edit&amp;section=12\" title=\"Edit section: External links\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h2>\n<ul><li><a rel=\"nofollow\" class=\"external text\" href=\"http://www.who.int/neglected_diseases/en/\">United Nations World Health Organization</a></li>\n<li><a rel=\"nofollow\" class=\"external text\" href=\"http://www.fda.gov/NewsEvents/Testimony/ucm216991.htm\">U.S. Food and Drug Administration</a></li>\n<li><a rel=\"nofollow\" class=\"external text\" href=\"http://www.gatesfoundation.org/topics/Pages/neglected-diseases.aspx\">Bill and Melinda Gates Foundation</a></li>\n<li><a rel=\"nofollow\" class=\"external text\" href=\"http://globalnetwork.org/\">Global Network for Neglected Tropical Diseases</a></li>\n<li><a rel=\"nofollow\" class=\"external text\" href=\"http://journals.plos.org/plosntds/article?id=10.1371/journal.pntd.0006038\">India\u2019s neglected tropical diseases</a></li>\n<li><a rel=\"nofollow\" class=\"external text\" href=\"https://www.thelancet.com/pdfs/journals/langlo/PIIS2214-109X(15)00185-0.pdf\">Neglected tropical disease targets must include morbidity</a></li>\n<li><a rel=\"nofollow\" class=\"external text\" href=\"http://journals.plos.org/plosntds/article?id=10.1371/journal.pntd.0005759\">Global health policy and neglected tropical diseases: Then, now, and in the years to come</a></li></ul>\n<div class=\"noprint metadata navbox\" role=\"navigation\" aria-label=\"Portals\" style=\"font-weight:bold;padding:0.4em 2em\"><ul style=\"margin:0.1em 0 0\"><li style=\"display:inline\"><span style=\"display:inline-block;white-space:nowrap\"><span style=\"margin:0 0.5em\"><a href=\"/wiki/File:WHO_Rod.svg\" class=\"image\"><img alt=\"WHO Rod.svg\" src=\"//upload.wikimedia.org/wikipedia/commons/thumb/d/d6/WHO_Rod.svg/9px-WHO_Rod.svg.png\" width=\"9\" height=\"21\" srcset=\"//upload.wikimedia.org/wikipedia/commons/thumb/d/d6/WHO_Rod.svg/13px-WHO_Rod.svg.png 1.5x, //upload.wikimedia.org/wikipedia/commons/thumb/d/d6/WHO_Rod.svg/18px-WHO_Rod.svg.png 2x\" data-file-width=\"107\" data-file-height=\"250\" /></a></span><a href=\"/wiki/Portal:Medicine\" title=\"Portal:Medicine\">Medicine portal</a></span></li></ul></div>\n\n<!-- \nNewPP limit report\nParsed by mw2170\nCached time: 20180919003441\nCache expiry: 1900800\nDynamic content: false\nCPU time usage: 0.232 seconds\nReal time usage: 0.271 seconds\nPreprocessor visited node count: 1165/1000000\nPreprocessor generated node count: 0/1500000\nPost\u2010expand include size: 14221/2097152 bytes\nTemplate argument size: 3163/2097152 bytes\nHighest expansion depth: 15/40\nExpensive parser function count: 5/500\nUnstrip recursion depth: 0/20\nUnstrip post\u2010expand size: 13340/5000000 bytes\nNumber of Wikibase entities loaded: 0/400\nLua time usage: 0.040/10.000 seconds\nLua memory usage: 1.63 MB/50 MB\n-->\n<!--\nTransclusion expansion time report (%,ms,calls,template)\n100.00%  161.048      1 -total\n 39.67%   63.887      1 Template:Cleanup\n 21.55%   34.709      1 Template:Reflist\n 19.59%   31.549      2 Template:Main_other\n 17.91%   28.851      1 Template:Ambox\n 16.76%   26.991      2 Template:Citation_needed\n 15.09%   24.300      5 Template:Category_handler\n 14.79%   23.817      2 Template:Fix\n  8.10%   13.045      2 Template:Delink\n  7.11%   11.443      1 Template:Portal_bar\n-->\n\n<!-- Saved in parser cache with key enwiki:pcache:idhash:30916247-0!canonical and timestamp 20180919003440 and revision id 844372195\n -->\n</div>"},"langlinks":[],"categories":[{"sortkey":"Neglected Tropical Disease Research And Development","hidden":"","*":"Articles_needing_cleanup_from_July_2011"},{"sortkey":"Neglected Tropical Disease Research And Development","hidden":"","*":"All_pages_needing_cleanup"},{"sortkey":"Neglected Tropical Disease Research And Development","hidden":"","*":"Cleanup_tagged_articles_without_a_reason_field_from_July_2011"},{"sortkey":"Neglected Tropical Disease Research And Development","hidden":"","*":"Wikipedia_pages_needing_cleanup_from_July_2011"},{"sortkey":"Neglected Tropical Disease Research And Development","hidden":"","*":"All_articles_with_unsourced_statements"},{"sortkey":"Neglected Tropical Disease Research And Development","hidden":"","*":"Articles_with_unsourced_statements_from_June_2012"},{"sortkey":"Neglected Tropical Disease Research And Development","*":"Tropical_diseases"},{"sortkey":"Neglected Tropical Disease Research And Development","*":"Medical_research"}],"links":[{"ns":14,"exists":"","*":"Category:Articles needing cleanup from July 2011"},{"ns":14,"exists":"","*":"Category:Cleanup tagged articles without a reason field from July 2011"},{"ns":14,"*":"Category:Wikipedia categories needing cleanup from July 2011"},{"ns":14,"exists":"","*":"Category:Wikipedia pages needing cleanup from July 2011"},{"ns":14,"exists":"","*":"Category:Articles with unsourced statements from June 2012"},{"ns":0,"exists":"","*":"Ascariasis"},{"ns":0,"exists":"","*":"Bill & Melinda Gates Foundation"},{"ns":0,"exists":"","*":"Bill and Melinda Gates Foundation"},{"ns":0,"exists":"","*":"Buruli ulcer"},{"ns":0,"exists":"","*":"Chagas' disease"},{"ns":0,"exists":"","*":"Chagas disease"},{"ns":0,"exists":"","*":"Cryptococcosis"},{"ns":0,"exists":"","*":"Cysticercosis"},{"ns":0,"exists":"","*":"Dengue fever"},{"ns":0,"exists":"","*":"Developing country"},{"ns":0,"exists":"","*":"Disability-adjusted life years"},{"ns":0,"exists":"","*":"Dracunculiasis"},{"ns":0,"exists":"","*":"Drug pipeline"},{"ns":0,"exists":"","*":"Echinococcosis"},{"ns":0,"exists":"","*":"Essential medicines"},{"ns":0,"exists":"","*":"European Medicines Agency"},{"ns":0,"exists":"","*":"Food and Drug Administration (United States)"},{"ns":0,"exists":"","*":"Food and Drug Administration Amendments Act of 2007"},{"ns":0,"exists":"","*":"HIV/AIDS"},{"ns":0,"exists":"","*":"Health Affairs"},{"ns":0,"exists":"","*":"Hilleman Laboratories"},{"ns":0,"exists":"","*":"Hookworm"},{"ns":0,"exists":"","*":"Hookworm infections"},{"ns":0,"exists":"","*":"Human African trypanosomiasis"},{"ns":0,"exists":"","*":"INSERM"},{"ns":0,"exists":"","*":"Infectious disease"},{"ns":0,"exists":"","*":"Institut Pasteur"},{"ns":0,"exists":"","*":"International Vaccine Institute"},{"ns":0,"exists":"","*":"Leishmaniasis"},{"ns":0,"exists":"","*":"Leprosy"},{"ns":0,"exists":"","*":"Lymphatic filariasis"},{"ns":0,"exists":"","*":"Malaria"},{"ns":0,"exists":"","*":"Mass drug administration"},{"ns":0,"exists":"","*":"Neglected tropical diseases"},{"ns":0,"exists":"","*":"Non-governmental organization"},{"ns":0,"exists":"","*":"Off-label use"},{"ns":0,"exists":"","*":"Onchocerciasis"},{"ns":0,"exists":"","*":"Open source"},{"ns":0,"exists":"","*":"Priority review voucher"},{"ns":0,"exists":"","*":"Public Private Partnerships"},{"ns":0,"exists":"","*":"Rabies"},{"ns":0,"exists":"","*":"Research and development"},{"ns":0,"exists":"","*":"Sabin Vaccine Institute"},{"ns":0,"exists":"","*":"Sam Brownback"},{"ns":0,"exists":"","*":"Sandler Foundation"},{"ns":0,"exists":"","*":"Schistosomiasis"},{"ns":0,"exists":"","*":"Social determinants of health"},{"ns":0,"exists":"","*":"Trachoma"},{"ns":0,"exists":"","*":"Trematode infection"},{"ns":0,"exists":"","*":"Trichuriasis"},{"ns":0,"exists":"","*":"Trypanosomiasis"},{"ns":0,"exists":"","*":"Tuberculosis"},{"ns":0,"exists":"","*":"Wellcome Trust"},{"ns":0,"exists":"","*":"World Health Organization"},{"ns":0,"exists":"","*":"X-Prize Foundation"},{"ns":0,"exists":"","*":"Yaws"},{"ns":4,"exists":"","*":"Wikipedia:Citation needed"},{"ns":4,"exists":"","*":"Wikipedia:Cleanup"},{"ns":4,"exists":"","*":"Wikipedia:Manual of Style"},{"ns":10,"exists":"","*":"Template:Cleanup/doc"},{"ns":12,"exists":"","*":"Help:Maintenance template removal"},{"ns":100,"exists":"","*":"Portal:Medicine"}],"templates":[{"ns":10,"exists":"","*":"Template:Cleanup"},{"ns":10,"exists":"","*":"Template:Main other"},{"ns":10,"exists":"","*":"Template:Ambox"},{"ns":10,"exists":"","*":"Template:SUBJECTSPACE formatted"},{"ns":10,"exists":"","*":"Template:Category handler"},{"ns":10,"exists":"","*":"Template:DMC"},{"ns":10,"exists":"","*":"Template:Dated maintenance category"},{"ns":10,"exists":"","*":"Template:FULLROOTPAGENAME"},{"ns":10,"exists":"","*":"Template:Ns has subpages"},{"ns":10,"exists":"","*":"Template:DMCA"},{"ns":10,"exists":"","*":"Template:Citation needed"},{"ns":10,"exists":"","*":"Template:Fix"},{"ns":10,"exists":"","*":"Template:Fix/category"},{"ns":10,"exists":"","*":"Template:Delink"},{"ns":10,"exists":"","*":"Template:Reflist"},{"ns":10,"exists":"","*":"Template:Column-width"},{"ns":10,"exists":"","*":"Template:Portal bar"},{"ns":828,"exists":"","*":"Module:Unsubst"},{"ns":828,"exists":"","*":"Module:Message box"},{"ns":828,"exists":"","*":"Module:No globals"},{"ns":828,"exists":"","*":"Module:Yesno"},{"ns":828,"exists":"","*":"Module:Arguments"},{"ns":828,"exists":"","*":"Module:Message box/configuration"},{"ns":828,"exists":"","*":"Module:Category handler"},{"ns":828,"exists":"","*":"Module:Category handler/data"},{"ns":828,"exists":"","*":"Module:Category handler/config"},{"ns":828,"exists":"","*":"Module:Category handler/shared"},{"ns":828,"exists":"","*":"Module:Category handler/blacklist"},{"ns":828,"exists":"","*":"Module:Namespace detect/data"},{"ns":828,"exists":"","*":"Module:Namespace detect/config"},{"ns":828,"exists":"","*":"Module:Ns has subpages"},{"ns":828,"exists":"","*":"Module:Delink"},{"ns":828,"exists":"","*":"Module:Check for unknown parameters"},{"ns":828,"exists":"","*":"Module:Portal bar"},{"ns":828,"exists":"","*":"Module:Portal"},{"ns":828,"exists":"","*":"Module:Portal/images/m"}],"images":["Edit-clear.svg","Ivermectin_skeletal.svg","Remy_Steinegger_-_World_Economic_Forum_-_Melinda_French_Gates,_Bill_Gates_-_World_Economic_Forum_Annual_Meeting_Davos_2009_(by-sa).jpg","DNDi_logo.JPG","WHO_Rod.svg"],"externallinks":["http://www.mectizan.org/","http://www.georgeinstitute.org/about-us/media-centre/g-finder-database-open-public","http://www.who.int/neglected_diseases/en/","http://www.fda.gov/NewsEvents/Testimony/ucm216991.htm","http://www.gatesfoundation.org/topics/Pages/neglected-diseases.aspx","http://globalnetwork.org/","http://journals.plos.org/plosntds/article?id=10.1371/journal.pntd.0006038","https://www.thelancet.com/pdfs/journals/langlo/PIIS2214-109X(15)00185-0.pdf","http://journals.plos.org/plosntds/article?id=10.1371/journal.pntd.0005759"],"sections":[{"toclevel":1,"level":"2","line":"Overview","number":"1","index":"1","fromtitle":"Neglected_tropical_disease_research_and_development","byteoffset":578,"anchor":"Overview"},{"toclevel":1,"level":"2","line":"NTD list","number":"2","index":"2","fromtitle":"Neglected_tropical_disease_research_and_development","byteoffset":3106,"anchor":"NTD_list"},{"toclevel":1,"level":"2","line":"Deficient market","number":"3","index":"3","fromtitle":"Neglected_tropical_disease_research_and_development","byteoffset":5023,"anchor":"Deficient_market"},{"toclevel":1,"level":"2","line":"Policy initiatives","number":"4","index":"4","fromtitle":"Neglected_tropical_disease_research_and_development","byteoffset":7593,"anchor":"Policy_initiatives"},{"toclevel":2,"level":"3","line":"Public private partnerships","number":"4.1","index":"5","fromtitle":"Neglected_tropical_disease_research_and_development","byteoffset":7617,"anchor":"Public_private_partnerships"},{"toclevel":2,"level":"3","line":"R&D capacity building in middle income countries","number":"4.2","index":"6","fromtitle":"Neglected_tropical_disease_research_and_development","byteoffset":8957,"anchor":"R&D_capacity_building_in_middle_income_countries"},{"toclevel":2,"level":"3","line":"Innovation prizes and grants","number":"4.3","index":"7","fromtitle":"Neglected_tropical_disease_research_and_development","byteoffset":10005,"anchor":"Innovation_prizes_and_grants"},{"toclevel":2,"level":"3","line":"FDA priority review vouchers (PRV)","number":"4.4","index":"8","fromtitle":"Neglected_tropical_disease_research_and_development","byteoffset":11086,"anchor":"FDA_priority_review_vouchers_(PRV)"},{"toclevel":2,"level":"3","line":"Open source collaboration initiatives","number":"4.5","index":"9","fromtitle":"Neglected_tropical_disease_research_and_development","byteoffset":12810,"anchor":"Open_source_collaboration_initiatives"},{"toclevel":1,"level":"2","line":"References","number":"5","index":"10","fromtitle":"Neglected_tropical_disease_research_and_development","byteoffset":13938,"anchor":"References"},{"toclevel":1,"level":"2","line":"Further reading","number":"6","index":"11","fromtitle":"Neglected_tropical_disease_research_and_development","byteoffset":18603,"anchor":"Further_reading"},{"toclevel":1,"level":"2","line":"External links","number":"7","index":"12","fromtitle":"Neglected_tropical_disease_research_and_development","byteoffset":39829,"anchor":"External_links"}],"parsewarnings":[],"displaytitle":"Neglected tropical disease research and development","iwlinks":[],"properties":[{"name":"defaultsort","*":"Neglected Tropical Disease Research And Development"},{"name":"wikibase_item","*":"Q6987375"}]}}